Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up
DOI:
https://doi.org/10.1080/00015550410030682Abstract
We present here the course of clinical response of a 53-year-old haemodialysed Fabry patient who received recombinant human alpha-galactosidase A at a dose of 1 mg/kg every other week over a period of 1 year. The therapy was well tolerated by the patient, who revealed an impressive favourable cutaneous, gastrointestinal, neurological and psychiatric response and a dramatic improvement in his quality of life, but no improvement in cardiac and renal function.Downloads
Download data is not yet available.
Downloads
Published
2004-09-17
How to Cite
Tsambaos D, C. E. (2004). Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up. Acta Dermato-Venereologica, 84(5), 389–392. https://doi.org/10.1080/00015550410030682
Issue
Section
Articles
License
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
